TomoTherapy files registration statement for IPO
The Madison-based medical device manufacturer has filed a...
Mission Statement 2003: Do More with Less and Do it Faster!
Every company that hopes to survive in 2003 has an unambiguous mission
statement: Do more with less, and do it faster! But how? Funding and resources are strained to the limit, marketing is getting more like a snipe hunt, and (remaining) personnel are having to do the jobs of two to three people. Companies are already doing more with less; is it possible under these conditions to do any...
Lupus Foundation of America Statement on Results for Clinical Study
of CellCept Released by Aspreva Pharmaceutical Company
Statement by Sandra C. Raymond, President & CEO of the LupusFoundation of America, Inc. WASHINGTON, June 27, 2007 /PRNewswire-USNewswire/ -- The LupusFoundation of America, Inc. and more than 1.5 million Americanswith lupus have been awaiting the preliminary findings of the PhaseIII clinical trials for CellCept(R), a potential treatment forlupus kidney disease being tested by Aspreva...
Obama Statement on Bush Veto of Stem Cell Bill
CHICAGO--(BUSINESS WIRE)--Jun 20, 2007 - Senator Obama todayreleased the following
statement in response to President Bush'sveto of Stem Cell Bill: "By vetoing funding for stem cell research once again, thePresident is deferring the hopes of millions of Americans who donot have the time to keep waiting for the cure that may save orextend their lives. The promise that stem cells hold does...
Statement by Philip Home Chairman of the RECORD Study Steering
Committee and Professor of Diabetes Medicine at Newcastle
University in England
"The editorials published by the NEJM are disappointing andmisleading in that they disregarded important pieces of data thatare extremely relevant to patients and physicians. Mostsignificantly the editorials ignored data that showed no evidenceof any increase in cardiovascular death or death from anycause."...
New Position Statement from The North American Menopause Society
Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in
Postmenopausal Women
CLEVELAND--(BUSINESS WIRE)--May 10, 2007 - An evaluation of thesafety and effectiveness of local vaginal estrogen therapy for thetreatment of vaginal atrophy, a frequent complaint ofpostmenopausal women, has just been released by The North AmericanMenopause Society (NAMS). Entitled "The role of local vaginalestrogen for treatment of vaginal atrophy in postmenopausal women:2007 position stat...